Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysisCapsule Summary

• Main Authors: Thomas Graier, MD (Author), Wolfgang Weger, MD (Author), Paul-Gunther Sator, MD (Author), Wolfgang Salmhofer, MD (Author), Barbara Gruber, MD (Author), Constanze Jonak, MD (Author), Claudia Kölli, MD (Author), Martina Schütz-Bergmayr, MD (Author), Igor Vujic, MD (Author), Gudrun Ratzinger, MD (Author), Nina Häring, MD (Author), Clemens Painsi, MD, PhD (Author), Knut Prillinger, MD (Author), Alexander Mlynek, MD (Author), Hans Skvara, MD (Author), Hannes Trattner, MD (Author), Adrian Tanew, MD (Author), Roland Lichem, MD (Author), Christina Ellersdorfer, MD (Author), Franz Legat, MD (Author), Alexandra Gruber-Wackernagel, MD (Author), Angelika Hofer, MD (Author), Erich Schmiedberger, MSc (Author), Wolfram Hoetzenecker, MD, PhD (Author), Robert Müllegger, MD (Author), Werner Saxinger, MD (Author), Franz Quehenberger, PhD (Author), Peter Wolf, MD (Author)
• Format: Book
• Published: Elsevier, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Little is known about the effectiveness and drug survival associated with apremilast under real-world conditions. Objective: To investigate the influence of patient and disease characteristics on drug survival associated with apremilast and to elucidate clinical effectiveness with regard...